GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » PB Ratio

Redx Pharma (LSE:REDX) PB Ratio : 15.00 (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-21), Redx Pharma's share price is £0.15. Redx Pharma's Book Value per Share for the quarter that ended in Sep. 2023 was £0.01. Hence, Redx Pharma's PB Ratio of today is 15.00.

The historical rank and industry rank for Redx Pharma's PB Ratio or its related term are showing as below:

LSE:REDX' s PB Ratio Range Over the Past 10 Years
Min: 0.35   Med: 6.46   Max: 101
Current: 15

During the past 12 years, Redx Pharma's highest PB Ratio was 101.00. The lowest was 0.35. And the median was 6.46.

LSE:REDX's PB Ratio is ranked worse than
93.88% of 1323 companies
in the Biotechnology industry
Industry Median: 2.53 vs LSE:REDX: 15.00

During the past 12 months, Redx Pharma's average Book Value Per Share Growth Rate was -89.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 0.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -1.80% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Redx Pharma was 102.10% per year. The lowest was -55.40% per year. And the median was 1.40% per year.

Back to Basics: PB Ratio


Redx Pharma PB Ratio Historical Data

The historical data trend for Redx Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma PB Ratio Chart

Redx Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.66 56.47 17.81 5.71 26.00

Redx Pharma Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.81 37.25 5.71 6.89 26.00

Competitive Comparison of Redx Pharma's PB Ratio

For the Biotechnology subindustry, Redx Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redx Pharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Redx Pharma's PB Ratio falls into.



Redx Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Redx Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2023)
=0.15/0.01
=15.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Redx Pharma  (LSE:REDX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Redx Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Redx Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redx Pharma (LSE:REDX) Business Description

Traded in Other Exchanges
N/A
Address
Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines